Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Molecular Pharmacology

• Publication date

  1997-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1124/MOL.52.6.1000PMID 9396780
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked

  1997cited by this paper
• Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death.

  1997cited by this paper
• Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia.

  1997cited by this paper
• Identification of a novel regulatory domain in Bcl‐xL and Bcl‐2

  1997cited by this paper
• Modulation of the expression of Bcl-2 and related proteins in human leukemia cells by protein kinase C activators: relationship to effects on 1-[β-D-arabinofuranosyl]cytosine-induced apoptosis

  1997cited by this paper
• The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis

  1997cited by this paper
• Molecular thanatopsis: a discourse on the BCL2 family and cell death.

  1996cited by this paper
• Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells.

  1996influential reference
• Taxol induces bcl-2 phosphorylation and death of prostate cancer cells.

  1996cited by this paper
• Bcl-2 targets the protein kinase Raf-1 to mitochondria.

  1996cited by this paper
• Activation of the CPP32 protease in apoptosis induced by 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents.

  1996cited by this paper
• A license to kill.

  1996cited by this paper
• Bax-independent inhibition of apoptosis by Bcl-XL

  1996cited by this paper
• Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate

  1996cited by this paper
• Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L)

  1996cited by this paper
• Phosphorylation of Bcl-2 Protein and Association with p21Ras in Ras-induced Apoptosis (*)

  1996cited by this paper
• Intracellular metabolism of Ara-C and resulting DNA fragmentation and apoptosis of human AML HL-60 cells possessing disparate levels of Bcl-2 protein.

  1996cited by this paper
• Fas-induced Activation of the Cell Death-related Protease CPP32 Is Inhibited by Bcl-2 and by ICE Family Protease Inhibitors*

  1996cited by this paper
• Generation of reactive oxygen intermediates after treatment of blasts of acute myeloblastic leukemia with cytosine arabinoside: role of bcl-2.

  1996cited by this paper
• Molecular Ordering of the Cell Death Pathway

  1996cited by this paper
• BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells.

  1995cited by this paper
• Exit from G0 and entry into the cell cycle of cells expressing p21Sdi1 antisense RNA.

  1995cited by this paper
• Direction of p21ras-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2.

  1995cited by this paper
• Inactivation of Bcl-2 by phosphorylation.

  1995cited by this paper
• Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2.

  1995cited by this paper
• Premature p34cdc2 activation required for apoptosis.

  1994cited by this paper
• Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis.

  1994cited by this paper
• Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells.

  1994cited by this paper
• Attenuation of ceramide-induced apoptosis by diglyceride in human myeloid leukemia cells.

  1994cited by this paper
• Induction of a common pathway of apoptosis by staurosporine.

  1994cited by this paper
• Bcl-2 and the regulation of programmed cell death

  1994cited by this paper
• Modulation of 1-[beta-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C.

  1994cited by this paper
• 1-beta-D-Arabinofuranosylcytosine stimulates ceramide and diglyceride formation in HL-60 cells.

  1994cited by this paper
• High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy.

  1993cited by this paper
• Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA

  1993cited by this paper
• bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.

  1993cited by this paper
• Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.

  1993cited by this paper
• Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA.

  1992cited by this paper
• Rescue from programmed cell death in leukemic and normal myeloid cells.

  1991cited by this paper

• Drug Resistance in Cancer Therapy and the Role of Epigenetics

  2020cites this paper
• Drug resistance in cancer therapy and the possible role of epigenetics.

  2020cites this paper
• A Novel Therapeutic Approach in Acute Promyelocytic Leukemia with All-trans retinoic Acid and Cyclin-dependent Kinase Inhibitors

  2018cites this paper
• Breast Cancer Foundation ( to L . L . ) Supported in part by grantsPathways to Induce Apoptosis 1 Antiapoptotic Functions of Bcl-2 and Target Protein Kinase C Novel Extranuclear-targeted Anthracyclines Override the Updated

  2014cites this paper
• Mitochondrial ROS and involvement of Bcl-2 as a mitochondrial ROS regulator.

  2014cites this paper
• Combination of guanine arabinoside and Bcl‐2 inhibitor YC137 overcomes the cytarabine resistance in HL‐60 leukemia cell line

  2013cites this paper
• Apoptosis in Human Myeloid Leukemia Cells Differentiation and CDKI Expression while Enhancing Disrupts Phorbol 12-Myristate 13-Acetate-induced The Cyclin-dependent Kinase Inhibitor (CDKI) Flavopiridol

  2013cites this paper
• Novel Therapeutics for Chemotherapy-Resistant Acute Myeloid Leukaemia

  2012cites this paper
• CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle.

  2011cites this paper
• Toxicity of bryostatin-1 on the embryo-fetal development of Sprague-Dawley rats.

  2010cites this paper
• Rational targeting in acute promyelocytic leukemia.

  2010cites this paper
• Adhesion-Induced Drug Resistance in Leukemia Stem Cells

  2010cites this paper
• Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737

  2009cites this paper
• Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cβ inhibitor, in non-small cell lung cancer cells

  2008cites this paper
• Bryostatin-5 blocks stromal cell-derived factor-1 induced chemotaxis via desensitization and down-regulation of cell surface CXCR4 receptors.

  2008cites this paper
• Cytogenetic study of the induction mechanism of chromosome-type aberrations by 1-beta-D-arabinofuranosylcytosine.

  2007cites this paper
• Emerging Therapeutics for AML

  2007cites this paper
• Sanguinarine overcomes P-glycoprotein-mediated multidrug-resistance via induction of apoptosis and oncosis in CEM-VLB 1000 cells.

  2006cites this paper
• Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway

  2006cites this paper
• RETRACTION: Flavopiridol and Histone Deacetylase Inhibitors Promote Mitochondrial Injury and Cell Death in Human Leukemia Cells That Overexpress Bcl-2

  2006cites this paper
• Gemcitabine-Induced Activation of Checkpoint Signaling Pathways That Affect Tumor Cell Survival

  2005cites this paper
• Strategies of Protection of Normal Cells During Chemo- and Radio-Therapy Based on Modulation of Cell Cycle and Apoptotic Pathways

  2005cites this paper
• Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells

  2005cites this paper
• Improving cancer therapeutics by molecular profiling.

  2005cites this paper
• AND HISTONE DEACETYLASE INHIBITORS PROMOTE MITOCHONDRIAL INJURY AND CELL DEATH IN HUMAN LEUKEMIA CELLS OVEREXPRESSING BCL-2

  2005cites this paper
• Activated JNK brings about accelerated apoptosis of Bcl‐2‐overexpressing C6 glioma cells on treatment with tamoxifen

  2005cites this paper
• Development of Protein Kinase C and Cyclin-Dependent Kinase Inhibitors As Potentiators of Cytotoxic Drug Action in Leukemia

  2005cites this paper
• Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects.

  2005cites this paper
• Susceptibility to cytosine arabinoside (Ara-C)-induced cytotoxicity in human leukemia cell lines.

  2004cites this paper
• Kinase Inhibitors and Cytotoxic Drug Resistance

  2004cites this paper
• The biology of non-small-cell lung cancer: identifying new targets for rational therapy.

  2004cites this paper
• Protein Kinase C Targeting in Antineoplastic Treatment Strategies

  2004cites this paper
• Role of Bcl-2 family proteins and caspase-3 in sanguinarine-induced bimodal cell death

  2004cites this paper
• Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1.

  2004cites this paper
• Characterization of p21Ras‐mediated apoptosis induced by protein kinase C inhibition and application to human tumor cell lines

  2004cites this paper
• Phorbol ester‐induced cell death in PC‐12 cells overexpressing Bcl‐2 is dependent on the time at which cells are treated

  2004cites this paper
• Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms.

  2003influential citation
• Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways.

  2003cites this paper
• Induction of tumor necrosis factor by bryostatin 1 is involved in synergistic interactions with paclitaxel in human myeloid leukemia cells.

  2003cites this paper
• The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.

  2003cites this paper
• Functional evaluation of the apoptosome in renal cell carcinoma

  2003cites this paper
• The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.

  2003cites this paper
• Protein kinase C-dependent activation of the tumor necrosis factor receptor-mediated extrinsic cell death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol.

  2003cites this paper
• Protein Kinase C-dependent Activation of the Tumor Necrosis Factor Receptor-mediated Extrinsic Cell Death Pathway Underlies Enhanced Apoptosis in Human Myeloid Leukemia Cells Exposed to Bryostatin 1 and Flavopiridol 1

  2003cites this paper
• Protein Kinase C-dependent Activation of the Tumor Necrosis Factor Receptor-mediated Extrinsic Cell Death Pathway Underlies Enhanced Apoptosis in Human Myeloid Leukemia Cells Exposed to Bryostatin 1 and Flavopiridol1

  2003cites this paper
• Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cells

  2002cites this paper
• Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)

  2002cites this paper
• Novel extranuclear-targeted anthracyclines override the antiapoptotic functions of Bcl-2 and target protein kinase C pathways to induce apoptosis.

  2002cites this paper
• Caspase-3 colorimetric assay.

  2002cites this paper
• Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

  2002cites this paper
• Activity of protein kinase C modulates the apoptosis induced by polychlorinated biphenyls in human leukemic HL-60 cells.

  2002cites this paper
• Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)

  2002cites this paper
• CHAPTER 12 – BIOSYNTHETIC PRODUCTS FOR ANTICANCER DRUG DESIGN AND TREATMENT: THE BRYOSTATINS

  2002cites this paper
• Bryostatin 1 increases 1-beta-D-arabinofuranosylcytosine-induced cytochrome c release and apoptosis in human leukemia cells ectopically expressing Bcl-x(L).

  2002cites this paper
• Use of marine toxins in combination with cytotoxic drugs for induction of apoptosis in acute myelogenous leukaemia cells

  2002influential citation
• Induction of Apoptosis in Human Leukemia Cells by the CDK1 Inhibitor

  2002cites this paper
• 7-hydroxystaurosporine (UCN-01) and ionizing radiation combine to inhibit the growth of Bcl-2-overexpressing U937 leukemia cells through a non-apoptotic mechanism.

  2002cites this paper
• Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.

  2002cites this paper
• Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.

  2002cites this paper
• Cyclotherapy: Protection of Normal Cells and Unshielding of Cancer Cells

  2002cites this paper
• New drug development in non-hodgkin lymphomas

  2001cites this paper
• Molecular signals in anti-apoptotic survival pathways

  2001cites this paper
• Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells.

  2001cites this paper
• The Cyclin-dependent Kinase Inhibitor ( CDKI ) Flavopiridol Disrupts Phorbol 12-Myristate 13-Acetate-induced Differentiation and CDKI Expression while Enhancing Apoptosis in Human Myeloid Leukemia Cells 1

  2001cites this paper
• The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway

  2001cites this paper
• Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells.

  2001cites this paper
• Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway.

  2001cites this paper
• The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.

  2001cites this paper
• Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action.

  2001influential citation
• Modulation of protein kinase C in antitumor treatment.

  2001cites this paper
• International childhood Acute Lymphoblastic Leukemia workshop: Sausalito, CA, 30 November–1 December 2000

  2001cites this paper
• Staurosporine analogues - pharmacological toys or useful antitumour agents?

  2000cites this paper
• UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: a new generation of anti-cancer agents for the new century?

  2000cites this paper
• Apoptosis induction by a dopaminergic neurotoxin, 1-methyl-4-phenylpyridinium ion (MPP(+)), and inhibition by epidermal growth factor in GH3 cells.

  2000cites this paper
• Protein Kinase C Modulation and Anticancer Drug Response

  2000cites this paper
• Novel therapeutic agents for the treatment of myelodysplastic syndromes.

  2000cites this paper
• Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line, Reh.

  2000cites this paper
• Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01).

  2000cites this paper
• The Role of C-type Protein Kinases in Apoptosis

  2000cites this paper
• New Drugs for the Treament of Chronic Lymphocytic Leukemia

  2000cites this paper
• Chronic exposure to bryostatin-1 increases the radiosensitivity of U937 leukaemia cells ectopically expressing Bcl-2 through a non-apoptotic mechanism.

  2000cites this paper
• New agents for acute myelogenous leukemia

  2000cites this paper
• The staurosporine analog, Ro-31-8220, induces apoptosis independently of its ability to inhibit protein kinase C

  2000cites this paper
• Programmed Cell Death in 2′,3′-dideoxycytidine-resistant Human Monoblastoid U937 Cells

  2000cites this paper
• Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh.

  1999cites this paper
• Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis.

  1999cites this paper
• Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL

  1999cites this paper
• Inhibition of the MAPK pathway abrogates BCL2-mediated survival of leukemia cells after exposure to low-dose ionizing radiation.

  1999cites this paper
• Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.

  1999cites this paper
• Pharmacology and clinical experience with bryostatin 1: a novel anticancer drug.

  1999cites this paper
• Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

  1999cites this paper
• Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin 1

  1999cites this paper
• Phorbol ester inhibits DNA damage-induced apoptosis in U937 cells through activation of protein kinase C.

  1999cites this paper
• The effects of gemcitabine and TPA on PKC signaling in BG-1 human ovarian cancer cells.

  1998cites this paper
• The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity

  1998cites this paper
• Polypeptides intervenant dans le mecanisme de l'apoptose induit par la staurosporine

  1998cites this paper
• Cytosine arabinoside(ara-C)の作用機序,その概念の変遷

  1998cites this paper
• Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937).

  1998cites this paper
• Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-beta-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling.

  1998cites this paper
• Apoptosis in Bcr/abl-expressing Human Leukemia Cells Kinase Inhibitors Interact Synergistically with Sti571 to Induce Signal-regulated Kinase Kinase/mitogen-activated Protein Pharmacologic Mitogen-activated Protein/extracellular Updated Version Cited Articles Citing Articles E-mail Alerts Pharmacolo

  year unknowncites this paper